Swiss drug major Roche (ROG: SIX) yesterday released new data from the ADACTA study which showed that adult rheumatoid arthritis (RA) patients who received its RoActemra (tocilizumab) as single-agent therapy (without other DMARDs) experienced a significantly greater improvement in disease activity (DAS28 score reduction) after 24 weeks compared to patients who received adalimumab as single-agent therapy.
Results from ADACTA showed that after 24 weeks of treatment patients with severe active RA and intolerance or inadequate response to MTX:
• achieved a mean improvement in disease activity (DAS28 score reduction) of 3.3 with RoActemra versus 1.8 with adalimumab;
• had a DAS28 remission rate of 40% with RoActemra versus 11% with adalimumab (DAS28 <2.6); and
• achieved ACR20, 50 and 702 responses of 65%, 47% and 33% with RoActemra versus 49%, 28% and 18% with adalimumab
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze